MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.

By M. Eslam, A. Sanyal, J. George. Gastroenterology, 2020

2,705 citations recorded by the source corpus.

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. While pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge and metabolic (dysfunction) associated fatty liver disease "MAFLD" was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and sub-phenotype the disease in order to accelerate the translational path to new treatments.

Subfields: Cell Biology, Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/0ef71e24707c5a34c03e8331bf12bac44b28524d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. P. Newsome

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. R. Loomba
4. Q. Anstee
5. K. Cusi
6. A. Sanyal
7. E. Bugianesi
8. Megan H. Bair-Merritt

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. R. Loomba
4. K. Cusi
5. A. Sanyal
6. Q. Anstee
7. S. Harrison
8. Vincent Wai-Sun Wong

Citations in the corpus

• Epidemiology of metabolic dysfunction-associated steatotic liver disease (2024, background): “[12] Additionally, many felt that the use of “fatty” in the name was associated with stigma which may be associated with the low awareness of NAFLD and hesitancy of individuals and health care workers to discuss this disease with their patients.”
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023, positive): “Thiswas summarised in a paper by Eslam et al., [6,7] in 2020 and led to the proposal to use the term metabolic dysfunction − associated fatty liver disease (MAFLD), which includes patients with a fatty liver regardless of the amount and pattern of alcohol intake under this terminology.”